Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, Freeman GJ, Boland GM, Luster AD.

Immunity. 2019 Jun 18;50(6):1498-1512.e5. doi: 10.1016/j.immuni.2019.04.010. Epub 2019 May 13.

PMID:
31097342
2.

MICROBIOLOGICAL SAFETY ASSESSMENT AND RISK MITIGATION OF INDIAN ROJAK (DEEP FRIED READYTO-EAT FOOD) IN SINGAPORE.

Aung KT, Lo JACY, Chau ML, Kang JSL, Yap HM, GutiƩrrez RA, Yuk HG, Ng LC.

Southeast Asian J Trop Med Public Health. 2016 Nov;47(6):1231-45.

PMID:
29634190
3.
4.

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.

Lo JA, Fisher DE, Flaherty KT.

JAMA Oncol. 2015 Dec;1(9):1340-1. doi: 10.1001/jamaoncol.2015.2274. No abstract available.

5.

The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.

Lo JA, Fisher DE.

Science. 2014 Nov 21;346(6212):945-9. doi: 10.1126/science.1253735. Review.

6.

A structure-based mechanism for tRNA and retroviral RNA remodelling during primer annealing.

Miller SB, Yildiz FZ, Lo JA, Wang B, D'Souza VM.

Nature. 2014 Nov 27;515(7528):591-5. doi: 10.1038/nature13709. Epub 2014 Sep 7.

PMID:
25209668
7.

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA.

Cancer Immunol Res. 2014 Jul;2(7):643-54. doi: 10.1158/2326-6066.CIR-13-0215. Epub 2014 Apr 29.

Supplemental Content

Support Center